Analysts think CRMD stock price could increase by 90%
Nov 07, 2025, 12:25 PM
-1.91%
What does CRMD do
CorMedix is a pharmaceutical company based in New Jersey, focused on developing therapeutic products, notably DefenCath, an antimicrobial solution for preventing catheter-related bloodstream infections in kidney failure patients. The company went public in 2010 and has also sponsored research on taurolidine for rare pediatric tumors.
9 analysts think CRMD stock price will increase by 89.59%. The current median analyst target is $20.40 compared to a current stock price of $10.76. The lowest analysts target is $14.14 and the highest analyst target is $23.10.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.